



AGB-Pharma Modern Slavery & Human Trafficking Statement 2023

Below we set out the steps AGB-Pharma AB (including our UK operations), hereafter called AGB-Pharma, has taken and continues to take to understand and minimize the potential risk of modern slavery in our business and supply chains.

This statement is published in line with section 54(1) of the Modern Slavery Act 2015.

Our commitment to the principles of the Modern Slavery Act 2015

AGB-Pharma (UK) is committed to the principles of the Modern Slavery Act 2015 and to the abolition of modern slavery and human trafficking. AGB Pharma is committed to conducting business in a responsible and ethical manner, in respect to everyone's basic human rights and will not tolerate any form or semblance of slavery or human trafficking within our business or supply chains.

As an equal opportunities' employer, we're committed to creating and ensuring a non-discriminatory and respectful working environment for our staff. We want all our staff to feel confident that they can expose wrongdoing without any risk to themselves.

Our recruitment and people management processes are designed to ensure that all prospective employees are legally entitled to work in the UK or EU and to safeguard employees from any abuse or coercion.

We do not enter into business with any organisation in the UK or abroad, which knowingly supports or is found to be involved in slavery, servitude and forced or compulsory labour. We continually assess the risk of modern slavery and human trafficking within our business and supply chain, this may include but is not limited to:

- Reliance on low skilled workforce
- Dangerous or undesirable work
- Involvement of migrant workers
- Presence of labour intermediaries
- Long, complex, or non-transparent supply chains
- Child labour

Our supply chain

AGB-Pharma works with all its suppliers to ensure that slavery and human trafficking is not taking place at any point in any of their supply chains or in any part of their business. Ensuring all internal and external stakeholders have the appropriate quality-related certificates for all their business practices, this is verified through inspections and audits. This is in compliance with the Modern Slavery Act 2015.

Due to the nature of our business, we assess ourselves to have a low risk of modern slavery in our business and supply chains. Our supply chains are limited and we procure goods and services from a restricted range of UK and EU based suppliers. AGB-Pharma has a zero



tolerance for any supply chain partners they believe are involved in unethical business practices and will terminate such relationships with immediate effect.

Our team

We believe that the risk of modern slavery in our directly employed workforce is low. This is due to the highly regulated nature of our industry, our employees being largely educated or skilled, or undertaking work in controlled environments where there are established policies and processes. However, all AGB-Pharma (UK) employees are trained in all relevant internal and external codes of conduct to ensure both a knowledge and understanding of risks and are actively encouraged to report any malpractice or violation, without fear of recrimination.

This statement has been approved by the Board of AGB Pharma AB and Fredrik Lindberg, AGB-Pharma CEO, for the financial year ending 31st of December 2023.

Lund, Sweden 2023-12-21

A handwritten signature in blue ink, appearing to read 'Fredrik Lindberg', written over a horizontal line.

Fredrik Lindberg
CEO
AGB-Pharma AB